Literature DB >> 34864989

Downregulation of Dihydrotestosterone and Estradiol Levels by HEXIM1.

Fitya Mozar1, Vikas Sharma1, Shashank Gorityala2, Jeffrey M Albert3, Yan Xu2, Monica M Montano1.   

Abstract

We have previously reported that hexamethylene bis-acetamide inducible protein 1 (HEXIM1) inhibits the activity of ligand-bound estrogen receptor α (ERα) and the androgen receptor (AR) by disrupting the interaction between these receptors and positive transcriptional elongation factor b (P-TEFb) and attenuating RNA polymerase II (RNAPII) phosphorylation at serine 2. Functional consequences of the inhibition of transcriptional activity of ERα and AR by HEXIM1 include the inhibition of ERα- and AR-dependent gene expression, respectively, and the resulting attenuation of breast cancer (BCa) and prostate cancer (PCa) cell proliferation and growth. In our present study, we determined that HEXIM1 inhibited AKR1C3 expression in BCa and PCa cells. AKR1C3, also known as 17β-hydroxysteroid dehydrogenase (17β-HSD) type 5, is a key enzyme involved in the synthesis of 17β-estradiol (E2) and 5-dihydrotestosterone (DHT). Downregulation of AKR1C3 by HEXIM1 influenced E2 and DHT production, estrogen- and androgen-dependent gene expression, and cell proliferation. Our studies indicate that HEXIM1 has the unique ability to inhibit both the transcriptional activity of the ER and AR and the synthesis of the endogenous ligands of these receptors.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  AKR1C3; HEXIM1; breast cancer; prostate cancer

Mesh:

Substances:

Year:  2022        PMID: 34864989      PMCID: PMC8645165          DOI: 10.1210/endocr/bqab236

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   5.051


  37 in total

1.  HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability.

Authors:  I-Ju Yeh; Ndiya Ogba; Heather Bensigner; Scott M Welford; Monica M Montano
Journal:  Biochem J       Date:  2013-12-01       Impact factor: 3.857

2.  Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation.

Authors:  Nanhai He; Andrea C Pezda; Qiang Zhou
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

Review 3.  AKR1C3 as a target in castrate resistant prostate cancer.

Authors:  Adegoke O Adeniji; Mo Chen; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2013-06-06       Impact factor: 4.292

4.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Authors:  Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

5.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors:  R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

6.  HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb.

Authors:  Ndiya Ogba; Laura J Chaplin; Yong Qiu Doughman; Koh Fujinaga; Monica M Montano
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

7.  Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.

Authors:  Agus Rizal A H Hamid; Minja J Pfeiffer; Gerald W Verhaegh; Ewout Schaafsma; Andre Brandt; Fred C G J Sweep; John P M Sedelaar; Jack A Schalken
Journal:  Mol Med       Date:  2013-01-22       Impact factor: 6.354

8.  HEXIM1 is a critical determinant of the response to tamoxifen.

Authors:  W Ketchart; N Ogba; A Kresak; J M Albert; J J Pink; M M Montano
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

9.  Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis.

Authors:  W Ketchart; K M Smith; T Krupka; B M Wittmann; Y Hu; P A Rayman; Y Q Doughman; J M Albert; X Bai; J H Finke; Y Xu; A A Exner; M M Montano
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

10.  11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored.

Authors:  Elzette Pretorius; Donita J Africander; Maré Vlok; Meghan S Perkins; Jonathan Quanson; Karl-Heinz Storbeck
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.